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Abstract
Background Reducing the dose of efavirenz can improve
safety, reduce costs, and increase access for patients with HIV
infection. According to the World Health Organization, a
similar dosing strategy for all patient populations is desirable
for universal roll-out; however, it remains unknown whether
the 400 mg daily dose is adequate during pregnancy.
Methods We developed a mechanistic population phar-
macokinetic model using pooled data from women inclu-
ded in seven studies (1968 samples, 774 collected during
pregnancy). Total and free efavirenz exposure (AUC24 and
C12) were predicted for 400 (reduced) and 600 mg (stan-
dard) doses in both pregnant and non-pregnant women.
Results Using a 400 mg dose, the median efavirenz total
AUC24 and C12 during the third trimester of pregnancy
were 91 and 87% of values among non-pregnant women,
respectively. Furthermore, the median free efavirenz C12
and AUC24 were predicted to increase during pregnancy by
11 and 15%, respectively.
Conclusions It was predicted that reduced-dose efavirenz
provides adequate exposure during pregnancy. These
findings warrant prospective confirmation.
Key Points
Reduced-dose efavirenz (400 mg) is non-inferior to
standard-dose efavirenz (600 mg) for HIV treatment
and may be less toxic. Pregnancy impacts efavirenz
pharmacokinetics, however the question remains as
to whether efavirenz exposure at the reduced dose is
adequate for pregnant women?
Pregnancy is associated with a minimal decrease in
total efavirenz exposure, but predicted free
(pharmacologically active) exposure is not decreased.
Reduced-dose efavirenz likely provides adequate
efavirenz exposure during pregnancy.
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1 Introduction
In the past 20 years, the development of effective and safe
interventions for the prevention of mother-to-child trans-
mission (PMTCT) of HIV-1 has been one of the great
successes in global and public health [1]. World Health
Organization (WHO) antiretroviral treatment guidelines
currently recommend lifelong treatment for all pregnant
and breastfeeding women living with HIV [2]. In parts of
the world where HIV is most prevalent, the antiretroviral
drug efavirenz is a key component of antiretroviral treat-
ment and PMTCT of HIV due to its excellent antiviral
potency, long-term efficacy, once-daily dosing, generic
availability, and substantial data demonstrating its efficacy
and safety during pregnancy [3].
To date, the standard efavirenz 600 mg dose has been
approved by regulatory authorities such as the US FDA,
and recommended by major HIV treatment guidelines
[4, 5]; however, there has been global interest in reducing
the standard efavirenz dose, in part to avoid drug toxicities
but largely to reduce cost [6]. A 33% dose reduction may
translate into 3-year cost savings of up to US$336 million
[7], which could be critical in the efforts to advance uni-
versal access to antiretroviral therapy for HIV-infected
individuals. The ENCORE1 study was performed to assess
the efficacy of a reduced-dose of efavirenz (400 mg once
daily) versus standard of care (600 mg once daily). In this
study, conducted in non-pregnant, treatment-naive adults,
reduced-dose efavirenz was non-inferior to the standard
dose in terms of virologic response [8].
Lower efavirenz doses will inevitably lead to lower
efavirenz exposures. Efavirenz mid-dose interval (MDI)
concentrations lower than 0.7–1 mg/L have been associ-
ated with virological failure [9, 10]. Although the reduc-
tions in exposure seen with efavirenz 400 mg once daily
versus 600 mg were not clinically important in non-preg-
nant adults, the pharmacokinetics of antiretroviral drugs
may be altered, leading to a higher risk of subtherapeutic
exposures in that population [11]. In turn, this may lead to
treatment failure, emergence of drug-resistance, and
mother-to-child transmission of HIV [11]. Thus, it is
essential to get drug dosing right in pregnant women. For
example, efavirenz is highly albumin bound ([99%) and
primarily metabolized by the hepatic cytochrome P450
(CYP) 2B6 enzyme [4]. Consequently, pregnancy-induced
alterations in plasma albumin concentrations or hepatic
enzyme activities could change the pharmacokinetics [12].
In fact, several studies have investigated the impact of
pregnancy on the pharmacokinetics of efavirenz 600 mg
once daily. Although most studies found reduced efavirenz
exposure during pregnancy compared with postpartum for
the 600 mg regimen, the reductions were modest and
unlikely to be clinically relevant [13–15]; however, to date
no studies have been conducted to assess the adequacy of
drug exposures with a 400 mg dose in pregnancy.
The WHO strives to recommend a limited formulary of
preferred treatment options that is applicable across all
patient populations, and this knowledge gap regarding low-
dose efavirenz pharmacokinetics during pregnancy is an
important barrier towards universal roll-out of reduced-
dose efavirenz [6]. As it is pivotal to bridge this knowledge
gap, we performed a mechanistic pharmacokinetic analysis
of efavirenz in pregnant and non-pregnant women to assess
the adequacy of efavirenz exposure when reducing the
efavirenz dose.
2 Methods
2.1 Pharmacokinetic Data
Data from six studies (studies 2–7; Table 1) that included
HIV-positive subjects taking efavirenz were pooled
[13, 14, 16–19]. Only data from women were retained for
further analysis. Data from non-pregnant women were
added first to evaluate the general structural and stochastic
aspects of the model, and data from pregnant women were
then added to incorporate the pregnancy-related covariate
effects into the model. At each step, the structural model
was re-evaluated and the effect of pregnancy was imple-
mented and investigated. Data from study 1 were used for
external model evaluation.
In total, 1968 plasma samples from 258 women were
available. Of these women, 116 were only sampled when
the patient was not pregnant. For the remaining 142
women, samples were available when the patient was
pregnant and not pregnant (postpartum). Overall, 774
samples were taken during pregnancy (Table 1). In these
samples, total plasma concentrations were determined.
Women using potentially interacting concomitant medici-
nes (e.g. rifampicin or isoniazid) were excluded [14]. All
except five of the patients included received the standard
efavirenz 600 mg once-daily dose. Patient characteristics
for each study are summarized in Table 1.
2.2 Mechanistic Information Used
for Pharmacokinetic Modeling
Based on a review of published efavirenz pharmacokinetic
data and relevant pregnancy-related changes in physiology,
we took into account the following considerations and
made the following decisions prior to the modeling pro-
cess. This was prespecified in an analysis plan that was
circulated to all coauthors involved.
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To account for the relationship between hepatic sys-
temic and first-pass metabolism, we implemented a well-
stirred liver model (Eqs. 1, 2) [20].
CLhep=F ¼ Qhep;plasma  Eh ð1Þ
Eh ¼ CLint;hep  fu
Qhep;plasma þ CLint;hep  fu ð2Þ
Apparent hepatic clearance (CLhep/F;
F = bioavailability) is expressed as a function of hepatic
plasma flow (Qhep,plasma) and hepatic extraction ratio (Eh).
Eh is defined as a function of apparent intrinsic hepatic
clearance (CLint,hep/F), and fraction unbound (fu). With
regard to CLint,hep/F (i.e. enzyme pool), CYP2B6 genetic
polymorphisms have a clinically relevant impact on the
extent of efavirenz biotransformation [21]; therefore, we
assumed three subpopulations (metabolic phenotypes):
poor metabolizers (PMs), intermediate metabolizers
(IMs), and extensive metabolizers (EMs). If data on an
individual CYP2B6 genotype (CYP2B6 516G ? T and
983T ? C) were available, the women were assigned to a
subpopulation based on a classification proposed
previously: EMs (no variant allele at 516 or 983), IMs
(single variant allele at position 516 or 983), slow
metabolizer (two variant alleles, i.e. 516 TT, 983 CC, or
516 GT plus 983 TC), or very slow metabolizer (two
variant alleles at position 983). Further details can be found
in the study by Dooley et al. [14]. Additionally, pregnancy
can induce enzymatic pathways, but the available evidence
was not sufficiently convincing to a priori assume
pregnancy-related induction of CYP2B6 [22].
Since efavirenz is highly albumin-bound ([ 99%),
changes in albumin plasma concentrations can result in
relatively large differences in fu and, consequently, CLhep/
F [23]. This has been previously observed for other drugs
[24]. Another known factor affecting CLhep/F during
pregnancy is an increased Qhep,plasma, which is related to a
decrease in hematocrit (Ht) during pregnancy [22]. Addi-
tionally, cardiac output is higher during pregnancy,
potentially translating into an increased hepatic blood flow
(Qhep). However, based on the current body of literature,
we could not describe the magnitude or relevance of
changes in Qhep during pregnancy and therefore this was
not included and fixed to the literature values (109 L/h) for
non-pregnant women [22, 25]. A pregnancy-induced
increase in Qhep,plasma (Eq. 3) and decrease in fu (Eq. 4)
were included a priori using the following relations:
Qhep;plasma ¼ ð1 HtÞ  Qhep; ð3Þ
fu ¼ kDðkD þ ½PÞ : ð4Þ
Efavirenz protein (albumin)-binding dissociation
constant (kD) was fixed to the in vitro literature value,
2.05 lM [23]. For efavirenz, the range of free
concentrations encountered in vivo is much lower than
the kD [26], implying linear binding and an fu independent
of the free efavirenz concentration [27]. Polynomial
relations describing the relationship between gestational
age (GA) and albumin concentrations (P) (Eq. 5), as well
as Ht (Eq. 6), were used to predict pregnancy-induced
changes in fu and Qhep,plasma, respectively, on a population
level [22, 26].
½PðlMÞ ¼ ð45:8 0:1775  GA 0:0033  GA
2Þ
0:07
ð5Þ
½Ht(v/v %Þ ¼ 39:1 0:0544  GA 0:0021  GA2 ð6Þ
2.3 Population Pharmacokinetic Analysis
Data were analyzed using NONMEM 7.3.0 (ICON
Development Solutions, Hanover, MD, USA). The first-
order conditional estimation method was used with eta–
epsilon interaction. We used Pirana 2.9.1 (http://www.
pirana-software.com) as an interface for NONMEM to
structure and document model development [28]; R v3.2.2
(with Rstudio interface v1.0.136) for data preparation, and
graphical visualization and evaluation; and PsN 4.6.0 for
automation of a diverse range of processes related to model
development [29].
Several population pharmacokinetic models have been
developed for efavirenz but most were purely empirical
and not based on data from pregnant women. A model
previously developed by Dooley et al. [14] was both semi-
mechanistic and based on data from pregnant women,
hence this model was suitable as a starting point for further
development. We tested one- to three-compartmental dis-
tribution. Models tested to describe absorption included
zero- and first-order processes and implementation of
transit compartments to describe a gradual onset of
absorption. The transit rate constant (ktr) for the transit
compartments was estimated and the mean absorption time
(MAT) was calculated based on Eq. 7:
ktr ¼ nþ 1ð Þ=MAT ð7Þ
where n equals the number of transit compartments [30].
Because no data were available that allowed estimation of
absolute bioavailability, the typical value of bioavailability
was fixed to 1. For the estimation of model parameters, we
assumed log-normal distributions for the interindividual
variability (IIV) and interoccasion variability (IOV)
according to Eq. 8:
hi ¼ h  eðgiÞ ð8Þ
where hi is the individual parameter value, h is the typical
population value, and gi is the random effect drawn from a
normal distribution with mean 0 and variance x2.
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Correlations between random effects were evaluated and
included when identifiable and substantial ([ 30%). Each
occasion was defined as a pharmacokinetic assessment
visit, ranging from 1 to 6 assessments per individual.
Different residual error models with additive, proportional,
and combined error structures were tested.
To account for body-weight-induced changes in phar-
macokinetics a priori, all flow parameters and volumes
were scaled to a total non-pregnant body weight of 70 kg
according to allometric theory. The allometric exponents
were fixed to 3/4 for flow parameters and 1 for volumes of
distribution [31, 32].
2.4 Structured Covariate Analysis
Pregnancy was tested as a covariate (dichotomous) on all
estimated model parameters (CLint/F, Vc/F, Q, Vp/F, MAT,
and F) using a forward inclusion and backward elimination
approach. The covariate selection was based on scientific
and physiological plausibility and on maximum likelihood
statistics (quantified by the objective function value
[OFV]), with a 5% significance level (dOFV[- 3.84)
applied for likelihood ratio testing of nested models.
Backward elimination was based on a 1% significance
level (dOFV[- 6.64). The Akaike information criterion
was used for comparison of non-nested models.
2.5 Handling of Missing Covariates and Data Below
the Lower Limit of Quantification
Only one study included data for participant height. Con-
sequently, we did not explore and test the relation between
model parameters and body size descriptors other than
weight (e.g. fat-free mass). Data on the CYP2B6 genotype
in our population were limited (18%). In case of a missing
CYP2B6 genotype, a mixture model was implemented to
account for the multimodal distribution of CLint/F as a
result CYP2B6-related phenotypes: PMs, IMs, and EMs.
Subjects with missing genotype data were assigned to the
mixture (subpopulation) with the highest individual prob-
ability [33, 34]. The number of plasma concentrations
below the lower limit of quantification (LLOQ) for each
individual study was very low (\ 1%) and hence these data
were ignored.
2.6 Model Evaluation and Qualification
We evaluated precision in parameter estimates and stan-
dard goodness-of-fit plots. For the final model, parameter
uncertainty was obtained from the default covariance step
in NONMEM, as well as the sampling importance resam-
pling (SIR) procedure [35]. To further evaluate and qualify
the model for simulation, we used prediction corrected
visual predictive checks (pcVPC) [36]. In the case of a
model including a mixture, prediction correction cannot be
performed in a standard way since there can only be one
population prediction for each subpopulation to which the
subject can be assigned. To account for this, we employed
a strategy previously proposed for nevirapine [36]. Addi-
tionally, we conducted an external model evaluation to
further qualify the developed model. External model per-
formance was visually evaluated based on pcVPC, and
statistically based on the observations normalized predic-
tion distribution errors (NPDE), under the null hypothesis
that the model developed based on studies 2–7 adequately
describes the data from study 1, i.e. the NPDE follow an
N(0,1) distribution. This hypothesis was tested based on
three statistics as proposed by Brendel et al.: (1) Student’s
t test for the mean; (2) Fisher’s test for variance; and (3)
Shapiro–Wilks test for the distribution [37, 38].
2.7 Simulation
The final model was used to simulate efavirenz concen-
trations for women during the third trimester of pregnancy,
as well as non-pregnant women. The third trimester of
pregnancy was chosen since the risks of mother-to-child
transmission are highest during late pregnancy and labor
[39]. In addition, absolute differences in pharmacokinetics
are expected to be highest during the third trimester.
Simulations (5009/phenotype) were performed for efavir-
enz 400 and 600 mg once daily, assuming linear pharma-
cokinetics over this dosing range [4]. Bodyweights used for
simulation were randomly drawn from a log-normal dis-
tribution with geometric mean ± geometric standard
deviation (SD) of 62 ± 1.3 kg, based on the distribution
found in our data. GA during the third trimester of preg-
nancy was drawn from a normal distribution with a
mean ± SD of 34 ± 2.3 weeks, based on the distribution
found in our data. Secondary steady-state pharmacokinetic
parameters of total concentrations at steady state (AUC24
and C12) were derived, and the C12 were then compared
with the suggested mid-dose target concentrations for
efavirenz pharmacotherapy, i.e. 1 and 0.7 mg/L [9, 10].
Additionally, we explored the predicted free efavirenz
plasma AUC24 and C12 as these parameters are a better
proxy for the pharmacologically active concentration at the
site of action and are not biased by pregnancy-induced
changes in drug-protein binding [40]. This was carried out
using the predicted (concentration-independent) fu based
on GA and the model predicted individual total efavirenz
plasma concentration (Ctot), using Eq. 9:
Cfree ¼ fu  Ctot: ð9Þ
To evaluate the free efavirenz C12, the therapeutic target
of 0.7 mg/L was multiplied by the predicted fu in the non-
Reduced-Dose Efavirenz During Pregnancy 1425
pregnant population, providing a free efavirenz target
plasma concentration of 0.002 mg/L.
3 Results
In addition to the well-stirred liver model, a two-com-
partment disposition model with first-order elimination and
absorption through three absorption transit compartments
best described the data (Fig. 1). IIV was included for CLint/
F (DOFV - 52) and MAT (DOFV - 51). The associated
correlation was minor (6%) and was not included. IOV was
included for F (DOFV - 63). The inclusion of IOV for
other pharmacokinetic parameters led to over-parameteri-
zation and model instability. The residual error structure
was proportional. We explored separate error models (also
for different studies), but the changes were minor and
neither resulted in changes in parameter estimates nor
improved residual versus prediction goodness-of-fit plots;
hence this strategy was abandoned. Overall, no indication
of bias was observed.
Initially, the mixture population frequencies were esti-
mated. This led to model instability, and stochastic simu-
lation and estimation showed that the population
frequencies of the mixture could not be numerically iden-
tified. Therefore, population frequencies were fixed to 14,
36 and 50% for the PMs, IMs and EMs, respectively, based
on the available data on race or region (Table 1) combined
with reported prevalence of the CYP2B6 genotypes in
these races/regions in several studies (c.516G[T) [DOFV
- 309; p\ 0.001] [41–43]. Efavirenz has properties rela-
ted to auto-induction, but this could not be identified
because almost all data available contained information at
steady-state only [4]. Final population estimates are shown
in Table 2.
Based on the fixed mechanistic relations that we incor-
porated a priori, the pregnancy-related decrease in albumin
concentration over GA led to an increase in the fraction of
unbound efavirenz. This relationship is graphically pre-
sented in electronic supplementary material (ESM) 2. In
turn, this led to an increased apparent hepatic efavirenz
clearance over GA. The a priori implementation of this
relationship was accompanied by a DOFV of - 53. With
univariate testing of pregnancy on the pharmacokinetic
parameters, associations were found for Vc (DOFV - 22;
p\ 0.001), F (DOFV - 15; p\ 0.001), and MAT (DOFV
- 35; p\ 0.001). Forward inclusion and stepwise elimi-
nation led to the inclusion of parameter–pregnancy rela-
tionships for MAT and F (total DOFV - 49; p\ 0.001).
Further details can be found in ESM 2.
Standard goodness-of-fit plots of the final model indi-
cated no bias in the structural model, or unaccounted
heterogeneity in the data (Fig. 2). A pcVPC stratified for
pregnancy based on 500 samples is shown in Fig. 3. The
pcVPC indicated that the model has internal predictive
value in terms of both structural and stochastic model
components. The pcVPC stratified for pregnancy based on
500 samples for the external model evaluation indicated
that the model developed based on the data from studies
2–7 adequately described the data from study 1. This was
further supported by the evaluation of the observations
NPDE based on 2500 samples, as the null hypothesis (an
N(0,1) distribution) could not be rejected based on the three
statistics specified in the Methods section, using a 10%
significance level (p[ 0.1; pcVPC and NPDE diagnostic
plots are shown in ESM 1). This indicated that besides
internal predictive performance, the developed model has
adequate external predictive performance, and, altogether,
qualified the model for further use in the simulation phase
of this study. An a posteriori power evaluation using Monte
Carlo Mapped Power (available in PsN), based on the
number of paired (pregnant versus non-pregnant) obser-
vations available in our dataset, indicated[ 80% power to
detect pregnancy covariate effects (C 20%) for all struc-
tural model parameters, except those associated with the
peripheral compartment (data not shown) [44].
The simulated total efavirenz steady-state pharmacoki-
netic parameters (AUC24 and C12) following oral admin-
istration of efavirenz 600 and 400 mg once daily are shown
in Table 3, stratified for pregnancy as well as metabolizer
status. During the third trimester of pregnancy, the median
AUC24 and C12 across all phenotypes were 91 and 87%,
respectively, when compared with non-pregnant women.
Fig. 1 Final structural model. Efavirenz is absorbed through three
transit compartments into the liver compartment, based on four
identical first-order rate constants. For the first pass through the liver,
a fraction of the efavirenz amount is extracted and cleared, and the
fraction of the amount remaining reaches the systemic circulation and
becomes available for redistribution into the peripheral compartment.
Efavirenz recirculates from the central compartment to the liver with
a flow equivalent to liver plasma flow, and at each pass the liver
extracts a further fraction. ktr first-order rate constant, Eh fraction of
efavirenz extracted, Qh liver plasma flow, N number of transit
compartments, CLh hepatic clearance, Q intercompartmental clear-
ance, Vh, Vc and Vp volume of ditribution of the liver, central and
peripheral compartments, respectively
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Table 2 Final parameter
estimates
Parameter Parameter estimate RSE (%) RSE (%) from SIR
MAT (h) 2.12 7 7
MAT (h) in pregnant women 1.67 2 4
CLint/F (L/h)
a
Poor 1380 6 7
Intermediate 3340 8 6
Extensive 4580 6 5
Vc/F (L)
a 133 7 6
Vp/F (L)
a 390 5 6
Q/F (L/h)a 35 7 7
F (%) relative to non-pregnant women 116 5 4
IIV CLint/F (%) 32 7 14
IIV MAT (%) 44 8 15
IOV F (%) 24 4 12
Proportional residual error (%) 18 1 5
MAT mean absorption time (three transit compartments), CLint/F intrinsic clearance, Vc/F central volume of
distribution, Vp/F peripheral volume of distribution, Q/F intercompartmental clearance, F relative
bioavailability, IIV interindividual variability, IOV interoccasion variability, SIR sampling importance
resampling, RSE relative standard error
aThe data refer to a typical individual of 70 kg
Fig. 2 Standard goodness-of-fit plots for the final model. a Observed
concentration versus individual-predicted concentration around the
line of unity. b Observed concentration versus population-predicted
concentration around the line of unity. c CWRES versus population-
predicted concentrations. d Conditional weighted residual versus time
after dose. The dotted lines represent the 95% limits of the assumed
CWRES distribution (i.e. 0 ± 1.96). CWRES conditional weighted
residual
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Fig. 3 pcVPC of the final model for efavirenz 600 mg stratified for
pregnancy. The observations are indicated by the open circles. The
median (continuous line) and 5th and 95th percentiles (dashed line) of
the observations are shown, as well as the 95% confidence interval
around the median (pink-shaded areas) and 5th and 95th percentiles
(purple-shaded areas) of the simulated data. pcVPC prediction
corrected visual predictive checks
Table 3 Median (IQR) total efavirenz exposure (AUC24 and C12) and the percentage of simulated (C12) below 1 and 0.7 mg/L following
administration of efavirenz 400 and 600 mg once daily to pregnant (third trimester) and non-pregnant women, stratified for metabolizer status
Parameter PM IM EM
Non-pregnant
Efavirenz 600 mg QD
AUC, mg/hL 154 (121–194) 63 (50–80) 46 (37–61)
C12, mg/L 6.1 (4.6–7.9) 2.4 (1.8–3.2) 1.7 (1.2–2.3)
C12\ 1 mg/L 0% 3% 9%
C12\ 0.7 mg/L 0% 0% 2%
Efavirenz 400 mg QD
AUC, mg/hL 103 (81–130) 42 (33–54) 31 (24–41)
C12, mg/L 4.1 (3.1–5.2) 1.6 (1.2–2.1) 1.1 (0.81–1.5)
C12\ 1 mg/L 0% 15% 41%
C12\ 0.7 mg/L 0% 4% 14%
Pregnant, third trimester
Efavirenz 600 mg QD
AUC, mg/hL 140 (110–177) 57 (45–73) 42 (33–56)
C12, mg/L 5.4 (4.1–7.0) 2.1 (1.6–2.8) 1.4 (1.0–2.0)
C12\ 1 mg/L 0% 7% 23%
C12\ 0.7 mg/L 0% 1% 5%
Efavirenz 400 mg QD
AUC, mg/hL 93 (73–118) 38 (30–49) 28 (22–37)
C12, mg/L 3.9 (2.7–4.7) 1.4 (1.1–1.9) 1.0 (0.69–1.4)
C12\ 1 mg/L 0% 23% 53%
C12\ 0.7 mg/L 0% 8% 26%
PM poor metabolizer, IM intermediate metabolizer, EM extensive metabolizer, QD once daily, AUC area under the concentration–time curve,
AUC24 area under the concentration-time profile over the dosing interval, C12 mid-dose concentration
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The simulated total C12 during pregnancy compared with
non-pregnant women, stratified by phenotype, is plotted in
Fig. 4a. More subtherapeutic C12 was predicted during the
third trimester of pregnancy compared with non-pregnant
women for all phenotypes except the PMs. The percentage
of total C12 below 0.7 or 1 mg/L for SMs, IMs, and EMs
are reported in Table 3.
However, the simulated free C12 concentrations, based
on the individual predicted fu, were not lowered by preg-
nancy. Instead, the median free efavirenz C12 concentra-
tions are predicted to increase during pregnancy by 11%
(Fig. 4b). Overall, the median free efavirenz exposure
(AUC24,free) is predicted to be 15% higher during
pregnancy.
4 Discussion
In this study, we found a modest effect of pregnancy on the
efavirenz total AUC24 and C12—a 9 and 13% reduction
during the third trimester of pregnancy compared with non-
pregnant women, respectively. Previous pharmacokinetic
studies have indicated that pregnancy-related effects on the
standard efavirenz 600 mg regimen are limited and of
minor clinical relevance [13, 14]. In the current study, for
the newly proposed efavirenz 400 mg regimen, an increase
in the proportion of women having subtherapeutic total
drug concentrations was predicted during the third trime-
ster of pregnancy. Efavirenz C12 below 0.7 mg/L was
predicted for 19% of women with EM status during the
third trimester of pregnancy, compared with 9% for non-
pregnant women. Although the rate of C12 below 0.7 mg/L
for efavirenz 400 mg once daily was predicted to be twice
as high during the third trimester of pregnancy, the dif-
ference was mostly restricted to the EM subpopulation and,
in absolute terms, was small (median C12 of 1.0 vs. 1.1 mg/
L). Even lower protein-binding corrected concentrations
for 95% viral inhibition (PBIC95) have been suggested
based on in vitro assessments (0.13 mg/L [45]), but
translating in vitro to in vivo potency measures is not
straightforward for several reasons, including potential
interaction between the host, bug and drug, and that com-
bination antiretroviral therapy may alter the potency of an
individual antiretroviral agent [46]. Consequently, the
pharmacokinetic outcomes in this study were compared
against potency data from clinical studies that are also
routinely used in therapeutic drug monitoring, which
indeed may be conservative [45].
Fig. 4 Simulated a total and
b free concentrations following
administration of efavirenz
400 mg once daily during the
third trimester of pregnancy and
for non-pregnant women,
stratified by metabolizer status.
The horizontal dotted lines
represent the total and free
efavirenz plasma target
concentrations of a 0.7 mg/L
and b 0.002 mg/L, respectively.
EFV efavirenz, QD once
daily. C12 mid-dose
concentration
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Importantly, because efavirenz is highly albumin-bound
([ 99%) and only the free concentrations (at the target site)
are related to the pharmacological effects, conclusions
solely based on total concentrations may be misleading
[40]. Ideally, the free efavirenz concentrations during
pregnancy would be measured, but no such data were
available for modeling and we relied on model predictions
to distinguish between total and free efavirenz concentra-
tions. Fortunately, the predicted free efavirenz exposure
was not decreased during pregnancy. This indicates that
any decrease in total efavirenz concentrations following
400 mg once daily is unlikely to be clinically relevant since
only the free efavirenz concentration is available for the
pharmacological effect at the site of action.
As no additional pregnancy-related covariate effects on
hepatic clearance were identified, the increase in hepatic
clearance during pregnancy can be primarily ascribed to
the pregnancy-related increase in fu. Physiologically, this
indicates the absence of a significant and relevant preg-
nancy-induced efavirenz biotransformation, such as
induction of the major efavirenz metabolizing enzyme
CYP2B6. Although pregnancy-related induction of
CYP2B6 has been suggested based on in vitro assays, to
date this has not been confirmed in vivo [47]. Since efa-
virenz has a low Eh, changes in fu should not alter free
efavirenz concentrations [27]. Consequently, the model-
predicted (minor) increase in free efavirenz exposure (C12
and AUC24) is most likely related to alterations in efavir-
enz relative bioavailability and MAT during pregnancy.
Reduced small intestine motility in pregnant women could
increase the incomplete efavirenz absorption and maintain
higher intestinal concentration gradients [12, 48]. Addi-
tionally, increased blood flow to the gastrointestinal tract
resulting from increased cardiac output during pregnancy
may result in an increased absorption rate and decreased
MAT [22]. This has been previously observed in a popu-
lation pharmacokinetic analysis [49].
For a model-based investigation of the efavirenz dose
reduction to 400 mg in pregnancy, accurate identification
of the pregnancy-related effects on the primary pharma-
cokinetic parameters was essential. Given that efavirenz
pharmacokinetics are highly variable and the effects of
pregnancy are relatively small, a large sample size is
needed for sufficient power to detect these effects [13].
Smaller studies with less informative design may not have
been capable of identifying these effects, but pooling the
data from multiple sources allowed us to investigate these
effects with higher statistical power. Furthermore, external
evaluation of a pharmacokinetic model for efavirenz in
pregnancy has not been performed. It should be noted that
the dataset used for external evaluation was relatively small
(other datasets were retained for sufficient statistical
power), limiting the ability to fully evaluate the external
predictive performance. Nevertheless, no indications of
misspecification were found. This was reassuring given the
mechanistic nature of the analysis, the associated
assumptions, and the implemented mixture model.
Pooling data also comes at a cost as it may introduce
bias related to interstudy differences. For example, a large
amount of data were from studies with a crossover design
(i.e. intrasubject comparison) [13, 14, 16, 50]. The post-
partum assessment served as the control for the non-preg-
nant situation, and it can be questioned to what extent
pregnancy-induced physiological processes have normal-
ized during the early postpartum period. Furthermore, the
timing of the postpartum assessment may vary between
studies. Fortunately, in the current study, postpartum
samples were mostly taken 4–6 weeks after delivery. Pre-
vious work indicated that this time span is sufficient for
relevant physiological processes to normalize, allowing us
to pool these data with other datasets from non-pregnant
women [51]. The impact of such interstudy differences was
monitored by means of stepwise integration of data from
different sources and continued goodness-of-fit evaluation.
Because the number of studies included in this analysis was
still limited, we did not include interstudy variability [36].
Another strength of this study is its mechanism-based
nature. Where purely empirical modeling of total concen-
trations would have led us to the conclusion that the
pregnancy-related effects on efavirenz 400 mg once daily
are modest and probably not relevant, our mechanism-
based approach allowed us to take inferences one step
further. Namely, our analysis suggests that even if exposure
in terms of total concentrations may be affected, free
concentrations are unlikely to be decreased and free efa-
virenz exposure following 400 mg once daily is thus suf-
ficient during pregnancy. To reach such a conclusion, it
was of paramount importance to ensure that the incorpo-
rated mechanistic information was valid and reasonable. To
ensure that the inclusion of mechanistic information relied
on evidence and quality, we prespecified all mechanistic
information to be included in the model. This allowed us to
statistically test the mechanistic relations included and
prevented us from enforcing effects that were absent in the
(clinical) data. For example, the pregnancy-related change
in fu increased hepatic efavirenz clearance. Although
seemingly more complex, this is basically a time-varying
parameter–covariate relationship between GA and (hep-
atic) plasma clearance, through predicted albumin levels
and fu.
There were some limitations to this study, including
pharmacodynamic data not being available (e.g. viral load)
from the vast majority of the studies included, which
limited our ability to assess the exposure–response rela-
tionship in this particular population. Consequently, we
relied on target concentrations for efavirenz established in
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previous pharmacokinetic–pharmacodynamic analyses. A
long-standing efavirenz target total drug concentration is
1 mg/L [9]. However, in the ENCORE1 study, the lower
400 mg once-daily dose was non-inferior to the standard
600 mg dose despite more observed subtherapeutic expo-
sure, defined as\ 1 mg/L [52]. This indicates that this
threshold is not fully evidence-based and is most likely
conservative. Another limitation is that data on individual
CYP2B6 genotypes were only available from one study
[14]. Nonetheless, we were able to differentiate between
metabolic phenotypes using the mixture model [33]. As
mentioned previously, free efavirenz concentrations were
not determined. In addition, the individual plasma albumin
concentrations were not available and we relied on pre-
dicted population albumin concentrations based on GA for
the prediction of free efavirenz concentrations. Potentially,
pregnancy-induced changes in albumin levels in women
included in the current study were substantially different
from that assumed from the literature. The albumin affinity
may also be different in several populations. These
potential confounders limit the ability to better explain
variability in CL/F and to rely on individual predicted free
efavirenz concentrations. However, on a population level,
the free efavirenz AUC24 and C12 provide useful insights
and hypothesis for further study.
5 Conclusions
Our model predicts a modest decrease in total efavirenz
exposure during the third trimester of pregnancy. For efa-
virenz 400 mg once daily, this decrease seems of minor
clinical relevance. Moreover, the model predicted that free,
pharmacologically active efavirenz exposure was not
decreased. These findings warrant prospective confirma-
tions by a clinical trial studying the pharmacokinetics
(preferably total and free efavirenz concentration), viro-
logic response, and safety. Currently, a prospective phar-
macokinetic study with the reduced-dose efavirenz in
pregnant women is being conducted (NCT02499874).
When the outcomes of this trial are positive and in line
with our findings, the proposed dose reduction to efavirenz
400 mg can also be extended to pregnant women.
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